Yuanming Xu

Company: Pfizer

Job title: Associate Director - Translational Oncology Lead

Seminars:

Navigating the Maze: Challenges & Strategies for Combination Immunotherapies in Early-Phase Clinical Trials 9:00 am

• Achieving impressive monotherapy efficacy in late lines/post PDx pts has a very low likelihood • The true value of an IO agent resides in adding clinical benefit on top of standard of care or rational combo with new agents • How to select and assess cancer immunotherapy combinations in early-phase clinical studies (based upon…Read more

day: Day One